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Superinfection exclusion is the ability of an established virus infection to interfere with infection by a second
virus. In this study, we found that Huh-7.5 cells acutely infected with hepatitis C virus (HCV) genotype 2a
(chimeric strain J6/JFH) and cells harboring HCV genotype 1a, 1b, or 2a full-length or subgenomic replicons
were resistant to infection with cell culture-produced HCV (HCVcc). Replicon-containing cells became per-
missive for HCVcc infection after treatment with an HCV-specific protease inhibitor. With the exception of cells
harboring a J6/JFH-FLneo replicon, infected or replicon-containing cells were permissive for HCV pseudopar-
ticle (HCVpp) entry, demonstrating a postentry superinfection block downstream of primary translation. The
surprising resistance of J6/JFH-FLneo replicon-containing cells to HCVpp infection suggested a defect in virus
entry. This block was due to reduced expression of the HCV coreceptor CD81. Further analyses indicated that
J6/JFH may be toxic for cells expressing high levels of CD81, thus selecting for a CD81low population. CD81
down regulation was not observed in acutely infected cells, suggesting that this may not be a general mecha-
nism of HCV superinfection exclusion. Thus, HCV establishes superinfection exclusion at a postentry step, and
this effect is reversible by treatment of infected cells with antiviral compounds.
Hepatitis C virus (HCV) is an important human pathogen
associated with the development of chronic liver disease. It is
the type member of the Hepacivirus genus, which in addition to
the Pestivirus and Flavivirus genera comprises the family Fla-
viviridae. Viruses within the family Flaviviridae are enveloped
with a single-stranded RNA genome of positive polarity (re-
viewed in reference 33). Translation of the viral RNA genome
is driven by an internal ribosome entry site (IRES), generating
a polyprotein that is processed into structural and nonstruc-
tural proteins. The structural proteins, core (C), E1, and E2,
form the physical virion. The nonstructural proteins, p7-NS2-
NS3-NS4A-NS4B-NS5A-NS5B, form the viral replication
complex or assist in the assembly of virions.
Current understanding of HCV entry, translation, and rep-
lication events in cell culture has been learned through the use
of HCV full-length and subgenomic replicons (reviewed in
reference 2) and retroviral pseudoparticles bearing HCV E1
and E2 glycoproteins (HCVpp) (4, 19, 24). The recent devel-
opment of an infectious system that permits the growth of
HCV in cell culture (HCVcc) has enabled study of the com-
plete viral life cycle (30, 44, 51). Both HCVpp and HCVcc
entry is mediated by the E1 and E2 envelope glycoproteins,
proceeding in a CD81- and pH-dependent manner (23, 30, 44,
50, 51).
Superinfection exclusion, or homologous interference, is the
ability of an established virus infection to interfere with sec-
ondary virus infection. Multiple mechanisms that contribute to
superinfection exclusion have been demonstrated for various
viruses, including interference with receptor-mediated attach-
ment (10, 11, 41, 42) and penetration into cells (39, 40, 47), as
well as downstream replication events (1, 22, 26). We and
others have previously described superinfection exclusion for
the Pestivirus bovine viral diarrhea virus (BVDV) (29, 35) and
established that cells acutely infected with BVDV exhibit
blocks to superinfection at both the level of entry and viral
RNA replication (29).
In this study, we observed that cells acutely infected with HCV
genotype 2a chimeric strain J6/JFH and cells harboring HCV
RNAs from a range of genotypes were resistant to HCVcc
superinfection. Further analysis revealed that superinfection
was blocked downstream of viral entry. Unlike cells acutely
infected with J6/JFH and cells supporting Con1 and H77 full-
length, and Con1, H77, and JFH subgenomic replicons, cells
containing a persistent, full-length J6/JFH replicon were non-
permissive for HCVpp. Study of this HCVpp-resistant, stable
J6/JFH replicon population suggested that J6/JFH replication/
infection applies a strong negative selection for CD81-express-
ing cells. This observation could be mimicked at later time
points after infection with J6/JFH HCVcc.
MATERIALS AND METHODS
Cells and HCV-specific inhibitors. Huh-7.5 cells (9) were maintained in Dul-
becco’s modified Eagle’s medium supplemented with 10% heat-inactivated fetal
bovine serum (FBS) and 0.1 mM nonessential amino acids. Media and reagents
were purchased from GIBCO-BRL, Life Technologies Ltd. Replicon cells were
maintained in 0.5 mg/ml G418. BILN 2061 (28) and 2-C-methyladenosine (12)
were resuspended at a concentration of 10 mM in dimethyl sulfoxide (DMSO).
VSV stocks and plaque assays. Vesicular stomatitis virus (VSV) San Juan
strain stocks were generated by infection (multiplicity of infection [MOI] of 0.01)
of BHK-J cells (31) and collection of cell supernatants at approximately 17 h
* Corresponding author. Mailing address: Laboratory of Virology
and Infectious Diseases, Center for the Study of Hepatitis C, The
Rockefeller University, 1230 York Avenue, New York, NY 10021.
Phone: (212) 327-7046. Fax: (212) 327-7048. E-mail: ricec@mail
.rockefeller.edu.
 Published ahead of print on 7 February 2007.
3693











postinfection (hpi). For plaque assays, cells were seeded in six-well plates and
infected in duplicate with dilutions of virus. Cells were overlaid with 1 minimal
essential medium, 0.6% LE agarose, and 2.5% FBS, and incubated for 16 h when
they were fixed with 7% formaldehyde and stained with crystal violet. Plaques
were enumerated, and titers were expressed as PFU per milliliter.
Plasmid construction. pFLneo-J6/JFH was created via three-piece ligation of
a 9,903-bp Acc65I/SpeI fragment from pSGR/JFH1 (27), a 1,040-bp Acc65I/MfeI
fragment from pCR2/EMC-J6, and a 2,849-bp MfeI/SpeI fragment from pFL-
J6/JFH1 (30). pCR2/EMC-J6 was generated by TOPO-TA cloning into pCR2.1
(Invitrogen) of a PCR product containing the encephalomyocarditis virus
(EMCV) IRES fused to the core through the NS2 gene region of HCV strain J6.
This product was generated in two steps via overlap extension. One first-round
PCR utilized oligonucleotides RU-O-3841 (5-CTCTCCTCAAGCGTATTCAA
C-3) and RU-O-5720 (5-GGTATTATCGTGTTTTTCAAAGGAAAACCA-3)
to amplify the EMCV IRES from a derivative of Con1-SGneo (I) (7). The other
first-round PCR utilized oligonucleotides RU-O-5726 (5-TGGTTTTCCTTTGA
AAAACACGATAATACCATGAGCACAAATCCTAAACCTCAAAG-3) and
RU-O-5727 (5-GGCATAAGCAGTGATGGGAGCGAGAAGACTCCACCC
CTTG-3) to amplify the core to NS2 region of HCV-J6 from pJ6CF (48).
First-round PCR products were purified by using the QIAquick PCR purification
kit (QIAGEN) and used as templates in a second-round PCR with oligonucle-
otides RU-O-3841 and RU-O-5727. pSGR-JFH1 has been described previously
(27), and cells harboring this replicon (see below) will be referred to as JFH-
SGneo cells. Con1-FLneo (I) and Con1-SGneo (I) are full-length and sub-
genomic genotype 1b (Con1 isolate) constructs, respectively, which contain an
S2204I mutation in NS5A and have been described previously (7, 9) and will be
referred to here as Con1-FLneo and Con1-SGneo. H-FLneo and H-SGneo are
HCV genotype 1a (H77 isolate) full-length and subgenomic replicons, respec-
tively, that contain the adaptive mutations P1496L, V1880A, A1940V, and
C1968R, allowing for persistent replication of the H77 genome in Huh-7.5 cells.
These adaptive mutations were identified after transfection of Huh-7.5 cells with
H-SGneo (L) (8) and selection with G418 and subsequently reengineered into
the H-SGneo (L) or H-FLneo (L) backbone (J. Fan and C. M. Rice, unpublished
data).
RNA transcription and generation of HCV full-length and subgenomic repli-
con cell populations. FL-J6/JFH-5C19Rluc2AUbi, pFLneo-J6/JFH, and pSGR-
JFH1 RNAs were synthesized as described previously (43) by in vitro transcrip-
tion of an XbaI-linearized template using the T7 MEGAscript kit (Ambion) and
purification with the RNeasy mini kit (QIAGEN) with on-column DNase treat-
ment. Con1 and H77 constructs were linearized with ScaI or HpaI, respectively,
and utilized as templates for in vitro transcription as described above. J6/JFH-
FLneo, JFH-SGneo, Con1-FLneo, Con1-SGneo, H-FLneo, and H-SGneo rep-
licon cell populations were generated by electroporation of Huh-7.5 cells with 1
g of the corresponding in vitro-transcribed RNA, as described previously (43).
Replicon-containing cells were selected and maintained with 0.5 mg/ml G418.
Generation of FL-J6/JFH and HCVcc-Rluc virus stocks and HCVcc infections.
Stocks of FL-J6/JFH and FL-J6/JFH-5C19Rluc2AUbi (HCVcc-Rluc) were gen-
erated as described previously (30, 43) by electroporation of in vitro-transcribed
RNA into Huh-7.5 cells. For HCVcc-Rluc infections, cells were incubated with
undiluted virus (MOI of0.01) for 1 to 3 h at 37°C. Cells were then washed twice
with media, incubated for 24 h, and harvested for luciferase assays. For infections
including 2-methyladenosine, drug (1.35 M) was added to the media at the
time of infection and maintained during the 24-h incubation. At each time point,
cells (untreated or treated with inhibitor) were harvested from triplicate wells for
luciferase assays, and cells from duplicate wells were analyzed for HCV RNA
levels. All infections of neomycin-resistant cell populations were performed in
the absence of G418.
Generation of HCVpp stocks and HCVpp infection. HCV pseudoparticles
expressing firefly luciferase (HCVpp-Luc), VSV G protein pseudoparticles ex-
pressing firefly luciferase (VSVGpp-Luc,) and no-envelope control viruses were
generated in 293T cells as described previously (24) by cotransfection of an
envelope-deficient human immunodeficiency virus (HIV) genome (pNL4-
3.Luc.R.E) and a plasmid expressing HCV H77 (21) or J6 (34) viral glyco-
proteins E1 and E2, VSV G, or an empty vector (no envelope). For infection,
cells that had seeded in a 96-well plate were incubated with HCVpp, VSVGpp,
or no-envelope pseudoparticles in the presence of Polybrene (4 g/ml) for 6 to
12 h at 37°C. Luciferase activity was determined at 72 hpi. HCVpp relative
luciferase units (RLU) values were normalized to VSVGpp values for each
sample. Infections of neomycin-resistant cell populations were performed in the
absence of G418. To generate HCVpp expressing a green fluorescent protein
(GFP) reporter (HCVpp-GFP) and control VSVGpp-GFP, 293T cells were
cotransfected as described above with the CSGW HIV provirus encoding only
GFP (18), a plasmid expressing the HIV gag-pol genes, and either an HCV H77
E1 and E2 or the VSV G-protein expression plasmid. Infections were performed
as described above, and cells were harvested for flow cytometry at 48 hpi.
Luciferase assays. For Renilla (HCVcc expressing Renilla luciferase [HCVcc-
Rluc]) and firefly luciferase assays (HCVpp-Luc and VSVGpp-Luc), cells were
lysed with Renilla or cell culture lysis buffer (Promega), respectively. Lysates
were harvested and mixed with luciferase assay substrate (Promega), as sug-
gested by the manufacturer. Luciferase activity was measured using a Centro
LB960 luminometer (Berthold Technologies, Bad Wildbad, Germany). For
HCVcc-Rluc infections, RLU values were normalized to the number of viable
cells in each sample by quantitating total cellular ATP levels using the CellTiter-
Glo luminescent cell viability assay (Promega) according to the manufacturer’s
instructions. The normalization step was performed to control for differences in
cell size or viability that might exist among the various cell populations used in
this study.
Immunostaining and flow cytometry. For live-cell surface staining, cells were
detached by a brief treatment with trypsin and resuspended in 3% FBS-0.05%
sodium azide in phosphate-buffered saline (PBS). Cells were incubated with
anti-CD81 1.3.3.22 (Santa Cruz Biotechnology, Santa Cruz, CA) or purified
mouse immunoglobulin G1 (IgG) (BD Pharmingen, Franklin Lakes, NJ) primary
antibodies, washed with WB, then incubated with Alexa Fluor 488-conjugated
goat anti-mouse IgG secondary antibody (Molecular Probes, Carlsbad, CA).
Alternatively, cells were incubated with phycoerythrin-conjugated CD81 anti-
body (monoclonal antibody [MAb] JS-81; BD Pharmingen). Cells were washed,
fixed in 0.5% paraformaldehyde, and analyzed by flow cytometry on a FACS-
Calibur (Becton Dickinson), counting 104 cells. For total cell staining, cells were
detached as described above and fixed in 0.5% paraformaldehyde. Fixed cells
were permeabilized in 0.5% FBS-0.1% saponin in PBS and incubated with CD81
or isotype control primary antibody, followed by Alexa Fluor 488-conjugated
goat anti-mouse IgG secondary antibody. After the cells were washed, they were
analyzed by flow cytometry as described above. For CD81/NS5A costaining, live
cells were detached and stained with phycoerythrin-conjugated CD81 antibody
(MAb JS-81; BD Pharmingen), fixed with paraformaldehyde, permeabilized, and
stained for NS5A using anti-NS5A primary antibody (MAb 9E10) (30), followed
by Alexa Fluor 647-conjugated goat anti-mouse IgG2a-specific secondary anti-
body (Invitrogen). Cells were then analyzed by flow cytometry as described
above.
Immunoblotting. Cells were lysed in sodium dodecyl sulfate (SDS) loading
buffer (2% SDS, 100 mM Tris-Cl, pH 6.8, 20% glycerol). Proteins were separated
by 12% SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellu-
lose membrane. CD81 was detected using MAb JS-81 (BD Pharmingen), fol-
lowed by horseradish peroxidase-conjugated anti-mouse secondary antibody
(Pierce). -Actin was detected with MAb AC-15 (Sigma) and an anti-mouse
secondary antibody as described above. Detection was performed with the
SuperSignal West Pico chemiluminescent substrate (Pierce).
Transduction of J6/JFH-FLneo cells with TRIP-CD81 or TRIP-CD9. The
lentiviral vector TRIP expressing wild-type human CD81 (TRIP-CD81) or CD9
(TRIP-CD9) protein has been described previously (50). For transduction, cells
were incubated overnight with undiluted TRIP-CD81 or TRIP-CD9 lentivirus in
the presence of Polybrene (4 g/ml). Forty-eight hours posttransduction, CD81
surface expression was confirmed by immunostaining and flow cytometry, and
cells were infected with HCVpp-Luc (H77) as described above.
Real-time quantitative reverse transcription-PCR (RT-PCR). To amplify
CD81 RNA, total RNA was harvested using the RNeasy mini kit (QIAGEN).
Fifty to 150 ng of total cellular RNA was mixed with primers and probe specific
for CD81 or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA.
RNAs were amplified using the Platinum Quantitative reverse transcription-
PCR ThermoScript one-step system (Invitrogen) and detected with the ABI
Prism 7700 sequence detection system (PE Applied Biosystems, Foster City,
CA). cDNAs were generated by reverse transcription at 50°C for 30 min, fol-
lowed by inactivation of the reverse transcriptase at 95°C for 5 min. cDNAs were
amplified with 40 cycles of 95°C for 15 s and 60°C for 1 min. The CD81-specific
primers and 6-carboxyfluorescein-labeled probe were purchased from Applied
Biosystems using a TaqMan inventoried gene expression assay for CD81 (assay
identification code, Hs00174717_m1). GAPDH-specific primers and VIC-la-
beled probe were purchased from Applied Biosystems (catalog no. 4326317E).
CD81 RNA levels were normalized to the levels of GAPDH RNA.
HCV RNA was amplified from 50 ng of total RNA using the 3NTR Multi-
Code real-time quantitative RT-PCR system (EraGen) and detected as de-
scribed above with the ABI Prism 7700. cDNAs were generated by reverse
transcription at 45 to 60°C for 15 min (1 min per degree) and amplified with 40
cycles of 95°C for 20 s, 60°C for 30 s, and 72°C for 30 s. The sequence of the
forward primer, labeled with 5 6-carboxyfluorescein isoC (2-deoxy-5-methyl-
isocytidine) (Biosearch Technologies, Inc.), was 5-GGCTCCATCTTAGCCCT
3694 TSCHERNE ET AL. J. VIROL.











AGTC-3, and the sequence of the reverse primer was 5-AGTATCGGCACT
CTCTCTGCAGT-3.
Treatment of HCV replicon-containing cells with BILN 2061. HCV sub-
genomic replicon cell populations containing H-SGneo, Con1-SGneo, and JFH-
SGneo replicons were treated with 40 nM (H-SGneo and Con1-SGneo) or 5 M
BILN 2061 (JFH-SGneo) in DMSO, 10 or 20 the 50% effective concentra-
tion (EC50) determined in reference 30, respectively, in the absence of G418. The
medium was changed every 2 or 3 days. HCV RNA levels were determined in
BILN 2061- or DMSO-treated cells at 4 and 9 days posttreatment at which point
the cells were challenged with HCVcc-Rluc. The RLU values from each cell
population on day 4 or 9 were expressed as the percentage of the DMSO-treated
Huh-7.5 cell RLU on day 4 or 9, respectively. J6/JFH-FLneo replicon-containing
cells were treated with 5 M BILN 2061 or DMSO for 9 days, after which the
concentration of drug was raised to 20 M. HCV RNA levels were determined
at 4, 9, and 23 days posttreatment when they were analyzed for CD81 surface
expression and HCV RNA levels, and challenged with HCVpp-Luc (H77).
RESULTS
Superinfection exclusion in HCVcc-infected and replicon-
containing Huh-7.5 cells. To determine whether previous in-
fection with HCV renders cells resistant to secondary HCV
infection, we infected Huh-7.5 cells with the J6/JFH genotype
2a chimeric virus (MOI of 0.01). At 4 days postinfection (dpi),
when approximately 77% of cells stained positive for NS5A
antigen (data not shown), we challenged the cells that had
been acutely infected with J6/JFH, in parallel with naı¨ve Huh-
7.5 cells, with the HCVcc Renilla luciferase reporter virus FL-
J6/JFH-5C19Rluc2AUbi (43) (HCVcc-Rluc). Luciferase ac-
tivity resulting from HCVcc superinfection of J6/JFH-infected
cells was 10% of the Huh-7.5 luciferase signal, suggesting
that superinfection exclusion is established in HCV-infected
cells (Fig. 1A).
To determine whether superinfection exclusion occurs
across genotypes and in cells harboring long-term, persistent
HCV replication, we generated HCV genotype 1a, 1b, and 2a
full-length replicon-bearing cell populations. The bicistronic
RNAs, H-FLneo (genotype 1a, H77), Con1-FLneo (genotype
1b, Con1), and J6/JFH-FLneo (genotype 2a, J6/JFH chimera),
used to establish these replicon cells express the dominant
selectable marker neomycin N-acetyltransferase (neo), which
provides resistance to the drug G418 and thus allows stable
maintenance of cells harboring replicating HCV RNA. The
expression of neo is driven by the HCV IRES, while the EMCV
IRES drives translation of the HCV polyprotein in the down-
stream cistron.
Following challenge of H-FLneo, Con1-FLneo, and J6/JFH-
FLneo cells, as well as Huh-7.5 parental cells with HCVcc-Rluc
(MOI of 0.01), all of the replicon-containing cells were able to
efficiently exclude HCVcc, yielding 10% of the luciferase
activity of infected Huh-7.5 cells (Fig. 1B). This result indicates
that cells harboring HCV genotype 1a, 1b, or 2a, exhibit su-
perinfection exclusion against genotype 2a HCVcc, similar to
that observed in cells acutely infected with J6/JFH (Fig. 1A).
To rule out the possibility that resistance to HCV infection was
due to expression of the neo resistance gene by the HCV
replicons, we challenged Huh-7.5 cells, which had been tran-
siently transfected with a plasmid expressing neo, with HCVcc-
Rluc. Luciferase activity from the transfected cells was 	80%
of naı¨ve Huh-7.5 cells, despite similar levels of neomycin phos-
photransferase II expression compared to the HCV replicon-
containing cells (data not shown).
To establish if expression of the HCV structural-NS2 region
was required for superinfection exclusion, we challenged Huh-
7.5 cell populations selected for stable maintenance of H-
SGneo, Con1-SGneo, or JFH-SGneo RNAs, the subgenomic
counterparts of the full-length genomes described above.
These genomes express neo and HCV NS3-NS5B via the HCV
FIG. 1. Cells harboring HCV do not support HCVcc superinfec-
tion. (A) Huh-7.5 cells were infected with J6/JFH HCVcc and main-
tained in parallel with naı¨ve cells. At 4 dpi, when approximately 77%
of cells were NS5A positive, cells acutely infected with J6/JFH and
naı¨ve cells were superinfected with HCVcc-Rluc. Each bar, expressed
as the percentage of the Huh-7.5 cell RLU, is the average value of
triplicate wells; error bars show the standard deviations. RLU, relative
light units. (B) Huh-7.5 cells and HCV full-length or subgenomic
replicon-containing cells were infected with HCVcc-Rluc. Luciferase
activity was measured at 24 hpi. Values, expressed as the percentage of
Huh-7.5 RLU, are the combined data from two independent experi-
ments done in triplicate; error bars represent the standard errors of the
means. (C) Huh-7.5 cells and HCV replicon-containing cells were
infected with VSV and overlaid with agarose. After 16 h of incubation,
cells were fixed with formaldehyde and stained with crystal violet to
visualize plaques. Each bar is the mean titer from duplicate wells; error
bars represent the standard errors of the means.
VOL. 81, 2007 HCV SUPERINFECTION EXCLUSION 3695











IRES and EMCV IRES, respectively. Similar to the results
observed with cells containing a full-length replicon, luciferase
activity after infection of the cell populations containing HCV
subgenomic replicons with HCVcc-Rluc was reduced to 15%
compared to naı¨ve Huh-7.5 cells (Fig. 1B).
Infection of replicon-containing cells with VSV yielded titers
that were comparable to those observed on Huh-7.5 cells (Fig.
1C). This excludes the possibility that the observed HCVcc
superinfection exclusion was due to the induction of a nonspe-
cific antiviral state.
Treatment with BILN 2061 restores HCV permissiveness.
We treated the H-SGneo, Con1-SGneo, and JFH-SGneo rep-
licon-containing cells with the HCV-specific protease inhibitor
BILN 2061 and subsequently challenged with HCVcc-Rluc. At
4 days posttreatment, HCVcc permissiveness was partially re-
stored in H-SGneo, Con1-SGneo, and JFH-SGneo cells that
had been treated with BILN 2061, as RLU values from these
cells, and not from DMSO-treated cells, were at least 50% of
the values for Huh-7.5 control cells (Fig. 2A). The increase in
HCVcc permissiveness in BILN 2061-treated cells coincided
with an approximately 100-fold decrease in HCV RNA levels
compared to the DMSO-treated cells (Fig. 2B). By day 9 of
BILN 2061 treatment, viral RNA levels had decreased further,
and the cells became fully permissive for HCVcc infection. A
slight but unexpected decrease in luciferase activity was ob-
served in BILN 2061-treated Huh-7.5 cells at the later time
points. This was observed in several repetitions of the experi-
ment (data not shown), suggesting that prolonged BILN 2061
treatment may create a cellular environment less favorable for
HCV replication or select a subpopulation of less permissive
cells. In any case, the dramatic increase in HCVcc permissive-
ness observed in BILN 2061-treated replicon-containing cells
indicates that superinfection exclusion requires the continuing
presence of HCV RNA and/or proteins and is readily revers-
ible by treatment with specific antivirals.
Superinfection exclusion occurs downstream of viral entry.
Given that superinfection exclusion occurs at both entry and
replication for BVDV (29), we used HCVpp to examine HCV
entry in acutely infected or stable replicon-containing cell pop-
ulations. HCV glycoprotein-mediated HCVpp entry was mon-
itored via expression of luciferase from the encapsidated HIV
RNA genome (HCVpp-Luc) (4, 24). The luciferase activity of
cells acutely infected with J6/JFH (4 dpi, 77% HCV NS5A
positive; Fig. 1A) was similar to that of naı¨ve Huh-7.5 cells
when infected with HCVpp-Luc bearing J6 glycoproteins (Fig.
3A). This suggested a block downstream of entry, given the
resistance of this cell population to HCVcc.
Full-length and subgenomic HCV replicon-containing cells
were also challenged with HCVpp-Luc bearing J6 or H77 gly-
coproteins. With the exception of cells harboring the stable
J6/JFH-FLneo replicon, all of the replicon-containing cells
were fully permissive for HCVpp (Fig. 3B), suggesting that the
dominant mechanism(s) of HCVcc exclusion in these selected
cell populations was also postentry.
Unexpectedly, HCVpp-expressed luciferase activity in the
stable J6/JFH-FLneo replicon population was reduced 98%
(J6 HCVpp) and 80% (H77 HCVpp) compared to that in
control Huh-7.5 cells, in contrast to cells acutely infected with
J6/JFH, which were fully permissive to HCVpp (Fig. 3A).
These data suggest that in cells selected for long-term, persis-
tent J6/JFH-FLneo replication, there is an additional block at
the level of entry. We address this surprising observation in
more detail below.
Examination of the postentry superinfection block. To fur-
ther define the superinfection block, we determined whether
translation of incoming HCV RNA was inhibited. To monitor
translation in the absence of viral replication, JFH-SGneo rep-
licon and parental Huh-7.5 cells were infected with HCVcc-
Rluc in the presence of 2-C-methyladenosine, a nucleoside
inhibitor of the NS5B RNA-dependent RNA polymerase (12).
2-C-methyladenosine was used at a 50-fold excess over the
EC50 reported for HCV genotype 2a (30), and we confirmed
that HCV RNA levels in HCVcc-infected Huh-7.5 and JFH-
SGneo cells declined over the 24-h time course (data not
shown).
In the absence of 2-C-methyladenosine, luciferase activity
in HCVcc-infected Huh-7.5 cells steadily increased, and by 24
hpi, it was more than 10-fold greater than the level found in
JFH-SGneo replicon cells (Fig. 4A). When 2-C-methyladen-
osine was present during HCVcc-Rluc infection, luciferase ac-
tivity was maximal at 6 hpi and then decreased over 24 h in
both Huh-7.5 and JFH-SGneo cells (Fig. 4B). During this time,
luciferase activity was equivalent and even slightly greater in
FIG. 2. HCV subgenomic replicon-containing cells treated with an
HCV-specific protease inhibitor become permissive for HCVcc infec-
tion. (A) Huh-7.5, JFH-SGneo, Con1-SGneo, and H-SGneo cells were
treated with BILN 2061 or DMSO in the absence of G418 for 4 days
(4d) or 9 days (9d). BILN 2061- or DMSO-treated cells were infected
with HCVcc-Rluc in the absence of inhibitor, and samples were har-
vested for luciferase assays at 24 hpi. Black bars (DMSO-treated cells)
represent the average RLU value over days 4 and 9 for each DMSO-
treated cell population compared to that in Huh-7.5 cells. RLU values
from BILN 2061-treated cells (gray and white bars) on day 4 or 9 are
expressed as the percentage of the DMSO-treated Huh-7.5 RLU on
day 4 or 9, respectively. Each bar is the average value of triplicate wells;
error bars show the standard deviations. The data shown are repre-
sentative of at least two independent experiments. (B) HCV RNA
levels in DMSO- or BILN 2061-treated JFH-SGneo, Con1-SGneo, and
H-SGneo replicon-containing cells at 4 (gray bars) or 9 days (white
bars) posttreatment were determined by real-time quantitative RT-
PCR. Black bars (DMSO-treated cells) represent the average RNA
level over days 4 and 9 for each DMSO-treated cell population. Error
bars show the standard deviations.
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JFH-SGneo cells compared to Huh-7.5 cells (Fig. 4B), suggest-
ing that entry, uncoating, and primary translation were unaf-
fected by the presence of the HCV replicon. Similar levels of
luciferase activity were also observed in JFH-SGneo and Huh-
7.5 cells after transfection with a polymerase-defective lucifer-
ase reporter HCV RNA (data not shown). In addition, we
compared HCVcc-Rluc primary translation in BILN 2061-
cured JFH-SGneo cells to untreated JFH-SGneo cells. Similar
to what we had observed above in the presence of 2-C-methyl-
adenosine, the two cell types had similar HCV translation ca-
pacities (Fig. 4C). Moreover, we also found that the BILN
2061-cured and untreated JFH-SGneo cells supported similar
levels of translation after infection with a temperature-sensi-
tive Sindbis virus mutant, TOTO1101/Luc:ts110 (6), at the
nonpermissive temperature, which allows translation, but is
blocked for RNA replication (data not shown). Thus, these
data indicate that the superinfection block in JFH-SGneo cells
lies downstream from entry, uncoating, and primary transla-
tion.
An additional defect in J6/JFH-FLneo selected cells. We
further investigated the surprising observation that HCVpp
entry was blocked in the J6/JFH-FLneo cell population (Fig.
3B). A possible mechanism for restriction at the level of entry
is down regulation of or interference with an essential viral
receptor or coreceptor. The tetraspanin CD81, originally iden-
tified as an HCV E2 binding protein (37), is an essential HCV
coreceptor required for entry of HCVpp and HCVcc (re-
viewed in references 3 and 16). We examined CD81 surface
expression on J6/JFH-FLneo, JFH-SGneo, and Huh-7.5 pa-
rental cell lines by flow cytometry. While JFH-SGneo and
Huh-7.5 cells expressed similar levels of CD81 at the cell sur-
face (Fig. 5A), levels were greatly reduced on the J6/JFH-
FLneo cells (Fig. 5B). In addition, staining of permeabilized
cells, Western blot analysis of whole-cell lysates, and real-time
FIG. 3. Cells acutely infected with J6/JFH, but not cells harboring
a stable J6/JFH-FLneo replicon, are permissive for HCVpp infection.
(A) Huh-7.5 cells were infected with J6/JFH HCVcc and maintained in
parallel with naı¨ve cells. At 4 dpi, when approximately 77% of cells
were NS5A positive, cells acutely infected with J6/JFH and naı¨ve cells
were superinfected with HCVpp-Luc-bearing strain J6 glycoproteins.
Each bar, expressed as the percentage of the Huh-7.5 RLU, is the
average value of triplicate wells; error bars show the standard devia-
tions. (B) Huh-7.5 cells and HCV full-length or subgenomic replicon-
containing cells were infected with HCVpp-Luc bearing HCV geno-
type 1a strain H77 (black bars) or genotype 2a strain J6 (white bars)
glycoproteins or with VSVGpp-Luc. Luciferase activity was measured
at 72 hpi. HCVpp-Luc RLU were normalized to VSVGpp-Luc RLU
and expressed as a percentage of the Huh-7.5 cell RLU. Each bar
shows the combined data from at least two independent experiments
done in triplicate; error bars represent the standard errors of the
means.
FIG. 4. JFH-SGneo cells exhibit a postentry superinfection block.
(A) Huh-7.5 and JFH-SGneo cells were infected with HCVcc-Rluc. At
each time point, luciferase activity was determined from triplicate wells
and normalized to the average cellular ATP content for each cell type
at that time point. Each bar is the average value of triplicate wells;
error bars show standard deviations. (B and C) Huh-7.5 cells (B) or
BILN 2061-cured JFH-SGneo (C) and JFH-SGneo cells were infected
with HCVcc-Rluc in the presence of 2-C-methyladenosine. At each
time point, luciferase activity was determined from triplicate wells and
normalized to the average cellular ATP content for each cell type at
that time point. Each bar is the average value of triplicate wells; error
bars show standard deviations.
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quantitative RT-PCR revealed that total cellular CD81 protein
and RNA levels were also decreased in J6/JFH-FLneo cells
compared to Huh-7.5 cells (Fig. 5C, D, and E). In contrast,
CD81 expression on the surfaces of cell populations containing
HCV genotype 1a and 1b full-length and subgenomic replicons
and on cells acutely infected with J6/JFH was also examined
and found to be similar to parental Huh-7.5 cells (data not
shown), in keeping with the previous observation (Fig. 3) that
these cells were permissive for HCVpp infection. Additionally,
the levels of scavenger receptor BI, another proposed HCV
entry factor (5, 38) were similar to those in Huh-7.5 parental
cells in all of the replicon-containing cells tested, including
cells harboring the stable J6/JFH-FLneo replicon and cells
acutely infected with J6/JFH (data not shown).
We next determined whether reduced CD81 on J6/JFH-
FLneo-containing cells was responsible for the entry defect by
restoring CD81 expression. Transduction of the J6/JFH-FLneo
cells with the lentiviral vector TRIP-CD81 (50) efficiently re-
stored CD81 expression at the cell surface and permissiveness
to HCVpp-Luc to 150% of control Huh-7.5 cells (Fig. 6A and
B, J6/JFH-FLneo-CD81). In contrast, J6/JFH-FLneo cells
transduced with a lentivirus expressing the tetraspanin CD9
(TRIP-CD9), which does not bind E2 or support HCV entry,
was less than 3% of the level in Huh-7.5 cells (Fig. 6B). Thus,
overexpression of CD81 rescues infection by HCVpp, indicat-
ing that reduced CD81 surface expression is responsible for the
entry defect observed in J6/JFH-FLneo cells.
It was unclear whether RNA replication and HCV protein
expression by the J6/JFH-FLneo replicon was somehow down
regulating CD81 mRNA and/or protein levels or whether
G418 selection of the replicon-containing population was fa-
FIG. 5. Stable J6/JFH-FLneo replicon-containing cells have de-
creased CD81 protein and RNA levels. (A and B) Huh-7.5 (gray line),
JFH-SGneo (black line in panel A), and J6/JFH-FLneo (black line in
panel B) cells were surface stained for CD81 and analyzed by flow
cytometry. Dashed gray and black lines indicate the IgG isotype con-
trols for Huh-7.5 cells and the JFH-SGneo (A) or J6/JFH-FLneo cells
(B), respectively. Max, maximum. (C) Permeabilized Huh-7.5 (gray
line) and J6/JFH-FLneo (black line) cells were stained for total cell
CD81 protein expression and analyzed by flow cytometry. Dashed gray
and black lines indicate the IgG isotype controls for Huh-7.5 and
J6/JFH-FLneo cells, respectively. (D) Western blot for CD81 (
-
CD81) or actin (
-actin) protein expression in lysates from J6/JFH-
FLneo, Huh-7.5, and JFH-SGneo cells. (E) CD81 RNA was amplified
using real-time quantitative RT-PCR from total RNA derived from
Huh-7.5, J6/JFH-FLneo, and JFH-SGneo cells. Values were normal-
ized to GAPDH RNA levels for each sample and are expressed as
relative levels compared to those in Huh-7.5 cells. Values are the
combined data from three independent experiments done in triplicate;
error bars show standard errors of the means.
FIG. 6. Ectopic expression of CD81 renders stable J6/JFH-FLneo
replicon cells permissive for HCVpp infection. (A) Transduction of
J6/JFH-FLneo cells with TRIP-CD81 restores CD81 expression. J6/
JFH-FLneo (black lines), J6/JFH-FLneo-CD81 (shaded area), and
Huh-7.5 (gray lines) cells were surface stained for CD81 and analyzed
by flow cytometry. Dashed lines indicate the IgG isotype controls. Max,
maximum. (B) Huh-7.5, J6/JFH-FLneo, J6/JFH-FLneo-CD81, and J6/
JFH-FLneo-CD9 cells transduced with TRIP-CD9 were infected with
HCVpp-Luc (genotype 1a strain H77) or VSVGpp-Luc, and luciferase
activity was measured at 72 hpi. HCVpp-Luc RLU were normalized to
VSVGpp-Luc RLU. Each bar is the average value of triplicate wells;
error bars show the standard deviations.
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voring cells with low or absent CD81. We first examined
whether J6/JFH-FLneo cells would regain CD81 expression
and HCVpp permissiveness after treatment with BILN 2061.
Cells were treated with BILN 2061 at 20 to 50 the reported
EC50 (30) over a period of 23 days in the absence of G418. Cell
surface expression of CD81 and HCVpp-Luc permissiveness
were assessed after 4, 9, and 23 days of treatment. At 4 days,
J6/JFH-FLneo cells remained resistant to HCVpp-Luc infec-
tion despite a 100-fold reduction in HCV RNA levels (Fig. 7A
and data not shown). By 9 days, when HCV RNA levels had
fallen 1,000-fold, a small increase in luciferase signal was ob-
served. After 23 days of BILN 2061 treatment, HCV RNA
levels had fallen to background levels (0.005 RNA copies/
cell), and the cells became permissive for HCVpp-Luc infec-
tion with a concomitant increase in CD81 surface expression
(Fig. 7B). These results indicate that permissive cells express-
ing CD81 can emerge after curing the population of replicating
J6/JFH-FLneo.
We also examined this phenomenon during long-term J6/
JFH infection of Huh-7.5 cells. Cells were infected at an MOI
of approximately 0.3 (infected population) and maintained in
parallel with naı¨ve cells (naı¨ve population) for a period of 17
days. Both populations were analyzed for CD81 surface ex-
pression, NS5A expression, and permissiveness to HCVpp-
GFP or to VSVGpp-GFP as a control. Pseudoparticle-chal-
lenged cells were harvested at 48 hpi, stained for NS5A, and
analyzed by flow cytometry. The percentage of total GFP-
positive, i.e., HCVpp-infected cells, both NS5A positive and
NS5A negative, was normalized to the percentage of GFP-
positive cells from the VSVGpp-GFP infection.
After 1 or 2 days, the infected population was fully permis-
sive for HCVpp (Fig. 8A). Beginning at day 3 and continuing
through day 8, there was a decrease in the percentage of
GFP-positive cells compared to the naı¨ve population, which
correlated with increasing numbers of NS5A-positive cells in
the J6/JFH-infected population (Fig. 8A). However, the vast
majority of the cells that were HCVpp susceptible (	80%)
were also NS5A positive (Fig. 8B). This demonstrated that
cells productively infected with J6/JFH were fully permissive
for HCV entry. Regarding surface CD81 expression, NS5A-
positive and -negative cells had CD81 expression levels com-
parable to those of naı¨ve cells early in infection (3 and 4 days)
(Fig. 8C). After 6 days, surface CD81 on NS5A-positive cells
remained comparable (70%) to naı¨ve cells; however, CD81
expression on NS5A-negative cells was greatly reduced (10%
of the naı¨ve cell intensity; Fig. 8C). Interestingly, the appear-
ance of this distinct CD81low NS5A-negative population was
coincident with an observed cytopathic effect in the infected
population (data not shown) and a 65% reduction in HCVpp-
GFP permissiveness in the infected population (Fig. 8A). After
6 days and 8 days, NS5A-negative cells made up only a small
proportion (approximately 10%) of the J6/JFH-infected cell
population. However, this NS5A-negative fraction persisted
and increased in frequency to 	70% by the final time point,
day 17. Notably, the modest decrease in CD81 expression in
NS5A-positive cells at 6 days and 8 days was more apparent by
17 days (Fig. 8C). Unlike the J6/JFH-FLneo population, which
had been selected with G418 and undergone multiple passages,
we saw no decrease in CD81 RNA levels during the 17-day
J6/JFH infection (data not shown). These data suggest that
J6/JFH infection selects against cells expressing high levels of
CD81, possibly due to a cytopathic effect or retarded growth
kinetics, leaving CD81low, uninfected cells to emerge. This
scenario may also explain the low levels of CD81 and HCVpp
resistance that we observed in G418-selected cell populations
harboring the J6/JFH-FLneo replicon.
DISCUSSION
This report describes and investigates the mechanisms of
superinfection exclusion in human hepatoma cells infected
with HCV. Superinfection exclusion of HCVcc was observed in
cells acutely infected with J6/JFH and in cells containing full-
length and subgenomic replicons derived from genotype 1a, 1b,
FIG. 7. BILN 2061-treated, J6/JFH-FLneo replicon-containing
cells have increased CD81 surface expression and are permissive for
HCVpp infection. (A) J6/JFH-FLneo and Huh-7.5 parental cells were
treated with BILN 2061 or DMSO for a period of 23 days. At 4 days
(4d), 9 days (9d), and 23 days (23d) posttreatment, DMSO- and BILN
2061-treated cells were challenged with HCVpp-Luc or VSVGpp-Luc.
Luciferase activity was measured at 72 hpi, and HCVpp-Luc RLU
were normalized to VSVGpp-Luc RLU. Each bar, expressed as the
percentage of DMSO-treated Huh-7.5 RLU, is the average value of
triplicate wells; error bars show the standard deviations. (B) At 23 days
posttreatment, BILN 2061 (dashed, black line)- and DMSO (black
line)-treated J6/JFH-FLneo and Huh-7.5 (gray line) cells were immu-
nostained for CD81 surface expression and analyzed by flow cytom-
etry. Max, maximum.
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or 2a genomes. Treatment with an HCV-specific antiviral
agent restored permissiveness in these cells, indicating that the
superinfection exclusion phenotype was fully reversible and
that it required the presence of HCV RNA or proteins. We
determined that the block to superinfection in cells harboring
HCV replication was downstream from virus entry and trans-
lation of the incoming genome RNA, possibly at the level of
RNA replication. An additional, unexpected defect at virus
entry was observed in cells harboring a persistent full-length
J6/JFH-FLneo replicon. Further analyses revealed that this
block to HCV entry was due to the loss of CD81high cells within
selected or infected cell populations rather than to a classical
superinfection exclusion mechanism.
During acute infection, the Pestivirus BVDV establishes su-
perinfection blocks to both virus entry and RNA replication
(29). Our data indicate that the principal mechanism of super-
infection exclusion in cells harboring HCV replication lies
downstream from virus entry, uncoating, and translation of the
incoming genome RNA. Although it remains possible that a
transient block at the level of primary translation may exist
during acute infection, our data suggest that in JFH-SGneo
replicon-containing cells, the superinfection block is due to a
direct effect on a downstream event, most likely at one or more
steps in RNA replication.
Interference at the level of RNA replication has been pre-
viously examined in the HCV replicon system. HCV replica-
tion efficiency was inversely correlated with the amount of
replicon RNA transfected into Huh-7 cells (32). This effect was
dependent on the presence of the HCV NS3-NS5B replicase
proteins. In another study, replication capacity of a transfected
replicon was reduced in cells that harbored an existing, repli-
cating HCV genome (20). Similarly, in cells acutely infected
with BVDV, the block to superinfecting virus at the level of
replication was directly correlated with the level of the primary
virus replication (29). These results suggest that viral replica-
tion can sequester factors that are limiting and saturable in the
host cell, thereby interfering with superinfecting virus replica-
tion. There may also be competition for replication sites, which
are in specialized membrane compartments similar to those
observed during classical Flavivirus RNA replication (13–15,
45, 46).
In the course of our HCV superinfection exclusion study, we
made the surprising observation that G418-selected cells har-
boring the J6/JFH-FLneo replicon have an additional defect in
virus entry. J6/JFH-FLneo cells were resistant to HCVpp bear-
ing glycoproteins from J6 or H77, whereas cells acutely in-
fected with J6/JFH and cells harboring either genotype 1a or
1b replicons, and genotype 2a subgenomic replicon-bearing
cells were fully permissive. Given that the defect was specific to
selected J6/JFH-FLneo, but not subgenomic replicon-contain-
ing cells suggested that the phenotype was dependent on J6
C-NS2 expression (or an RNA element harbored in this re-
FIG. 8. J6/JFH infection of Huh-7.5 cells promotes the emergence of a CD81low cell population. Huh-7.5 cells were infected with HCVcc
(J6/JFH) at an MOI of 0.3 and maintained in parallel with naı¨ve cells. (A) At 1, 2, 3, 4, 6, and 8 dpi with J6/JFH, the infected and naı¨ve cell
populations were infected with HCVpp-GFP or VSVGpp-GFP. Cells were harvested at 48 hpi. Cells were stained for NS5A and analyzed by flow
cytometry for GFP and NS5A expression. The total number of GFP-positive cells resulting from HCVpp-GFP infection was normalized to the total
number of GFP-positive cells in the VSVGpp-GFP-infected samples. Values are expressed as a percentage of GFP-positive cells in the naı¨ve
population. (B) The J6/JFH-infected cell population, which was infected with HCVpp-GFP and stained for NS5A in panel A, was grouped into
NS5A-positive and NS5A-negative cells. GFP expression in NS5A-positive and NS5A-negative cells was determined and plotted as a percentage
of the total GFP-positive cells. (C) The J6/JFH-infected and naı¨ve cell populations were analyzed for CD81 surface expression and NS5A
expression using immunostaining and flow cytometry at 3, 4, 6, 8, and 17 dpi with J6/JFH. Cells were gated on NS5A-positive (black line) or
NS5A-negative (dashed, black line) cells, and CD81 expression was compared to the naı¨ve population (shaded area). The day postinfection (dpi)
and percentage of NS5A-positive cells at each time point are indicated above the plots. 3d, 3 days; Max, maximum.
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gion). Further analyses revealed that CD81 down regulation
was the mechanism responsible for this phenotype. Total and
cell surface CD81 protein and CD81 mRNA levels were dra-
matically reduced in J6/JFH-FLneo cells compared to parental
cells. Furthermore, ectopic expression of CD81 rendered J6/
JFH-FLneo cells fully permissive for HCVpp infection.
Two possibilities, among others, might explain the low levels
of CD81 mRNA in J6/JFH-FLneo cells: (i) HCV-dependent
down regulation of CD81 expression or (ii) a selective advan-
tage for cells with low or absent CD81 during G418 selection.
Consistent with the latter possibility, prolonged J6/JFH infec-
tion yielded a cell population that was increasingly resistant to
HCVpp infection, although NS5A-positive cells were readily
infected with HCVpp. When CD81 surface expression was
examined, it became evident that a population of CD81low
NS5A-negative cells had emerged within the J6/JFH-infected
cell culture, coincident with and subsequent to a virus-induced
cytopathic effect. The pathway by which J6/JFH infection leads
to cell death is unknown, but our data indicate that expression
of CD81 and the HCV J6 C-NS2 region are involved. Although
we did find some CD81low NS5A-positive cells at later stages of
J6/JFH infection, the absence of CD81 down regulation during
acute infection suggests that this may be due to inefficient
infection of cells with lower levels of CD81. Therefore, the
main mechanism of this resistance could not be attributed to a
classical superinfection exclusion block at the level of virus
entry, where replicating HCV prevents a secondary HCV in-
fection. Rather, selection occurs at the population level, and
resistance is due to an emerging population of CD81low cells
that are less permissive for HCV infection. Similar observa-
tions during persistent JFH-1 infection have been recently
reported by Zhong et al. (52).
The J6/JFH-FLneo population cured with BILN 2061 in the
absence of G418 regained CD81 expression and became per-
missive for HCVpp entry. Several possibilities either at the
population or single-cell level could account for restored CD81
expression. At the population level, CD81low cells might lose
their growth advantage over surviving CD81high cells in the
absence of J6/JFH-FLneo replication or infection. Restoration
of CD81 expression was slow and occurred after HCV RNA
reached background levels. This might indicate that CD81high
cells have only a subtle growth advantage over CD81low cells in
the absence of virus. Alternatively, at the single-cell level, slow
recovery of CD81 expression could be due to an intrinsically low
rate of CD81 protein accumulation or slowly reversible epigenetic
changes that down regulated CD81 expression and occurred due
to persistent J6/JFH-FLneo replication and infection.
CD81low cells emerged after prolonged J6/JFH HCVcc in-
fection or selection of G418-resistant populations harboring
J6/JFH replicons. However, this was not the case for sub-
genomic replicons or for full-length Con1 or H77 replicons.
One possible explanation for this genotype-specific difference
is that high-level expression of the J6 C-NS2 region driven by
the JFH replicase is required for CD81-dependent cytostatic or
cytotoxic effects. Similar high levels of expression may not be
achieved by the Con1- or H77-adapted replicons. Alterna-
tively, whatever toxic determinants lie within the C-NS2 region
may be specific for the genotype 2a isolates tested thus far (J6
and JFH [52]) and not present in the corresponding genotype
1a (H77) or 1b (Con1) proteins. However, another potentially
important difference is the ability of J6/JFH constructs to pro-
duce infectious virus in cell culture. In future experiments, it
will be interesting to explore these possibilities by examining
the properties of H77/JFH chimeras that are defective for virus
production versus those harboring adaptations that allow re-
lease of infectious virus (34a, 49; M. Evans et al., unpublished
data).
The in vivo relevance of HCV-induced cytotoxicity and the
role of the C-NS2 region and CD81 in this process requires
further study. One might argue that the genotype-specific dif-
ferences, the high level of replication driven by the thus far
unique nonadapted JFH-1 replicase, and the use of Huh-7 or
Huh-7.5 hepatoma cells make it unlikely that similar effects
will be seen in the HCV-infected liver. Certainly, the generally
accepted view that HCV-associated liver damage is immune
mediated, rather than a direct consequence of hepatocyte in-
fection, is consistent with this view. However, some instances
of acute fulminant hepatitis C or rapidly progressive hepatitis
in the posttransplant setting could be the result of HCV vari-
ants that are cytotoxic, either due to higher replication levels,
the production of toxic viral components, or both. In addition,
the level of hepatocyte CD81 expression is clearly one mech-
anism for controlling HCV infection that may also influence
pathogenesis. This could be modulated by the virus, the host
response to virus infection, or therapeutically. In this regard, it
will be interesting to examine possible heterogeneity in the
level of CD81 expression in HCV-infected and uninfected liver
tissue and determine whether there is a relationship between
CD81 levels, virus infection, and cell death.
The phenomenon of HCV superinfection exclusion, namely,
that infected cells are less permissive for replication of a sec-
ond infecting virus, has potentially important implications for
understanding HCV biology in vivo. First, the efficient block
for replication of the superinfecting genome would limit the
potential for RNA recombination to cells simultaneously in-
fected by two viruses or infected cells that were successfully
superinfected before the replication block was established.
This may, in part, explain the dearth of natural HCV recom-
binants that have been identified thus far despite numerous
examples of patients harboring more than one HCV genotype
(17, 25). Second, even less-fit HCV variants generated during
error-prone HCV replication have a chance for at least tran-
sient survival, assuming that they could productively infect a
target cell and efficiently exclude replication of the more-fit
parental virus. This could provide HCV with a larger pool of
variants to deal with immune or other selective pressures that
emerge during the course of infection (or treatment). The
observation that superinfection exclusion is reversible at the
cellular level suggests that interferon (9) or specific antiviral
(36; this study) treatment may “cure” cells, thereby expanding
the number of hepatocytes that are permissive for replication
of inhibitor-resistant variants. Finally, the phenomenon of su-
perinfection exclusion and the fact that HCV RNA levels are
regulated and plateau after transfection or infection suggest
that there are one or more limiting cellular components re-
quired for HCV RNA replication. Future work will hopefully
lead to the identification of these limiting factors and an un-
derstanding of how they regulate HCV RNA replication.
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